News round-up for 20-24 July by Megan Thomas, Content Team at DDW. This week’s news roundup highlights the latest advances in cancer research and treatment, from promising clinical trial updates to discoveries that could improve the body’s immune response to tumours. The top stories include progress in… Read More
Circio Holding and Avenue Biosciences have entered a research collaboration to combine their synergistic technologies to improve long-term expression of secreted proteins, relevant for treatment of a broad range of diseases. Secreting proteins from cells into surrounding tissue, or into circulation, opens new treatment opportunities beyond classical gene therapy for… Read More
Researchers at the Icahn School of Medicine at Mount Sinai have identified a specialised immune cell that builds and maintains powerful immune hubs inside tumours, a discovery that could help improve the effectiveness of cancer immunotherapies. The findings, published in Science, show that dendritic cell type 1 is essential for… Read More
Rege Nephro, a Japanese clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, has closed a financing round totalling approximately US$10.6 million. Through the issuance of Japan-Keep It Simple Security (J-KISS) share acquisition rights, proceeds are expected to support commercialisation activities for RN-014, the company’s lead… Read More
Intensity Therapeutics has administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The clinical biotechnology company is focused on the discovery and development of novel intratumoural cancer therapies that are designed to kill tumours and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology. The trial (NCT06358573) analyses… Read More
The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and The Michael J. Fox Foundation (MJFF) have announced a new US$5 million partnership to accelerate the development of minimally invasive biomarkers for measuring pathologies associated with Parkinson’s and Alzheimer’s diseases. Isobel Coleman, Chief Executive Officer of the Alzheimer’s Drug Discovery… Read More
Multiomics research services partner Novogene Europe has launched its Untargeted Metabolomics Service through its Cambridge Omics Centre. This new capability will help researchers across the UK and Europe to connect molecular data with biological function by adding metabolite-level insight to genomics, transcriptomics, microbiome and broader life science studies. Untargeted Metabolomics… Read More
We’re excited to announce the launch of Drug Discovery Innovators & Investors (DDII) – a new event series from Drug Discovery World. The three-part global event series focuses on technology, innovation, and investment in early-stage drug discovery. Bringing together senior executives, R&D leaders, lab managers, and decision-makers from pharma and… Read More
Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More
Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More
Held from 11–19 June 2026, CWOW welcomed more than 5,000 attendees across 37 venues, delivering over 280 sessions and bringing together investors, entrepreneurs, academics, policymakers, operators, local communities and the wider biotech and techbio community from across the UK and beyond. Read more about the event here. Below, DDW… Read More
KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More
Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More
KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More
Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More
KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More
